Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

ABBVIE INC.

(ABBV)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies
Most relevant news about ABBVIE INC.
10/21ASTRAZENECA : Puts Cancer Drug Trial On Hold Due To Safety Concerns
MT
10/18ABBVIE : Receives CHMP Positive Opinion for Risankizumab (SKYRIZI) for the Treatment of Ad..
AQ
10/18OYSTER POINT PHARMA : drug becomes first FDA-approved nasal spray to treat dry eyes
RE
10/15REVANCE THERAPEUTICS : U.S. FDA declines to approve Revance's frown-line treatment
RE
10/15ABBVIE : Says its Psoriatic Arthritis Drug Risankizumab Recommended by CHMP for Treatment ..
MT
10/15AbbVie Receives CHMP Positive Opinion for Risankizumab (SKYRIZI®) for the Treatment of ..
CI
10/15AbbVie Gets CHMP Positive Opinion for Risankizumab in Psoriatic Arthritis
DJ
10/14PRESS RELEASE : Roche's Gazyvaro shorter 90-minute infusion time approved in Europe for pe..
DJ
10/14ABBVIE INC. : Ex-dividend day for
FA
10/12ABBVIE : Allergan Aesthetics Launches Series of Initiatives to Support Breast Cancer Aware..
AQ
10/11Health Care Stocks Sliding in Late Monday Trading
MT
10/11Health Care Stocks Drifting Monday as Biotechs Climb
MT
10/08ABBVIE : Upadacitinib (RINVOQ) Met Primary and Most Ranked Secondary Endpoints in Phase 3 ..
AQ
10/08ABBVIE : RINVOQ (upadacitinib) Met Primary and All Ranked Secondary Endpoints in Phase 3 S..
AQ
10/07ABBVIE : Gets Health Canada's Approval for Rinvoq to Treat Atopic Dermatitis
MT
10/07ABBVIE : Health Canada Approves the Use of RINVOQ® (upadacitinib) for the Treatment of Adu..
AQ
10/07AbbVie Announces Health Canada Approves Use of RINVOQ® (Upadacitinib) for Treatment of ..
CI
10/07ABBVIE : Phase 3 Trial of Upadacitinib to Potentially Treat Chronic Back Pain Meets Primar..
MT
10/07ABBVIE : 's Upadacitinib (RINVOQ®) Met Primary and Most Ranked Secondary Endpoints in Phas..
PR
10/07ABBVIE : 's RINVOQ® (upadacitinib) Met Primary and All Ranked Secondary Endpoints in Phase..
PR
10/07AbbVie Announces Positive Top-Line Results from the First of Two Studies of the Phase 3..
CI
10/07AbbVie Sees Positive Results in Rinvoq Studies
DJ
10/05ABBVIE : to Host Third-Quarter 2021 Earnings Conference Call
PR
10/02ABBVIE : to Showcase New Data at the United European Gastroenterology (UEG) Week Virtual 2..
PR
10/02AbbVie to Showcase New Data at the United European Gastroenterology Week Virtual 2021
CI
10/01ABBVIE : Presents New Analyses Evaluating RINVOQ (upadacitinib) in Atopic Dermatitis Acros..
AQ
09/30AbbVie Inc. Presents Late-Breaking Data on Risankizumab (Skyrizi®) in Psoriatic Arthrit..
CI
09/30ABBVIE : Presents New Analyses Evaluating RINVOQ® (upadacitinib) in Atopic Dermatitis Acro..
PR
09/30AbbVie Inc. Presents New Analyses Evaluating RINVOQ® (Upadacitinib) in Atopic Dermatiti..
CI
09/29ABBVIE : FDA Approves QULIPTA (atogepant), the First and Only Oral CGRP Receptor Antagonis..
AQ
09/29ETF PREVIEW : ETFs, Futures on Track to Open Higher as Wall Street Shakes Off Concerns Ove..
MT
09/29ABBVIE : Qulipta Wins FDA Approval as Preventive Treatment of Migraine
MT
09/28AMGEN : U.S. FDA approves AbbVie's migraine prevention drug
RE
09/28AMGEN : U.S. FDA approves AbbVie's migraine prevention drug
RE
09/28ABBVIE : FDA Approves QULIPTA™ (atogepant), the First and Only Oral CGRP Receptor An..
PR
09/28The U.S. Food and Drug Administration Approves AbbVie Inc.'s QULIPTA for the Preventive..
CI
09/28AbbVie Says FDA Approves Qulipta as Migraine Treatment
DJ
09/23ABBVIE : Presents New Data Analyses for Growing Dermatology Portfolio at the 30th European..
PR
09/22ABBVIE : N.D. Ill. Finds That A Foreign Parent Corp. May Be Sued Under BPCIA Without The U..
AQ
09/21INCYTE : FDA approves Incyte's eczema cream with boxed warnings
RE
09/20ABBVIE : Seeks FDA Approval for Crohn's Disease Treatment Candidate
MT
09/20ABBVIE : Submits Regulatory Application to FDA for Risankizumab-rzaa (SKYRIZI®) for the Tr..
PR
09/20AbbVie Submits Regulatory Application to FDA for Risankizumab-rzaa (SKYRIZI®) for the T..
CI
09/16ABBVIE : Files Regulatory Applications in US and Europe for Upadacitinib to Treat Adults W..
MT
09/16ABBVIE : Submits Regulatory Applications to FDA and EMA for Upadacitinib (RINVOQ®) for the..
PR
09/16AbbVie Submits Regulatory Applications to FDA and EMA for Upadacitinib for the Treatmen..
CI
09/16AbbVie Submits Regulatory Applications for Treatment of Ulcerative Colitis
DJ
09/15China's biotech sector comes of age with big licensing deals, global ambitions
RE
09/14ABBVIE : and REGENXBIO Announce Eye Care Collaboration
AQ
09/14REGENXBIO : RBC Lifts Price Target on REGENXBIO to $55 From $50, Sees Eye Care Deal With A..
MT
09/13Health Care Stocks Still Adding to Afternoon Slide
MT
09/13Health Care Stocks Slipping Monday Afternoon
MT
09/13REGENXBIO : Partners with AbbVie to Commercialize RGX-314 for Retinal Eye Diseases
MT
09/13ABBVIE : Declares Quarterly Dividend
AQ
09/13ABBVIE : to Highlight Its Leadership in Movement Disorders at the International Parkinson ..
AQ
09/13APPLE : Energy, financials help Wall Street rise from bruising week
RE
09/13Wall Street Set for Rebound After Week of Losses
MT
09/13Regenxbio Shares Jump After Collaborating With AbbVie on Eye Therapy
DJ
09/13Health Care Stocks Up Slightly in Premarket Monday Activity
MT
09/13REGENXBIO : Wall Street set to recover from sharp weekly losses
RE
09/13Top Premarket Gainers
MT
09/13ABBVIE : REGENXBIO Join Forces on Therapy to Treat Chronic Eye Disorders
MT
09/13REGENXBIO : to receive $370 mln upfront in gene therapy deal with AbbVie
RE
09/13REGENXBIO : AbbVie, Regenxbio enter deal to develop retinal disease therapy
RE
09/13AbbVie, Regenxbio to Partner on Eye Therapy
DJ
09/10ABBVIE : Maintains Quarterly Cash Dividend at $1.30 a Share, Payable Nov. 15 to Shareholde..
MT
09/10ABBVIE : Declares Quarterly Dividend
PR
09/10AbbVie Inc. Declares Quarterly Dividend, Payable on November 15, 2021
CI
09/10ABBVIE : Clinical Trial of Investigational Epcoritamab (DuoBody-CD3xCD20) in Patients with..
AQ
09/10ABBVIE : to Highlight Its Leadership in Movement Disorders at the International Parkinson ..
PR
09/09ABBVIE : to Present at the Morgan Stanley Healthcare Conference
PR
09/09GENMAB A/S : The Lancet Publishes Positive Results Of Genmab's Epcoritamab Phase 1/2 Trial
MT
09/08ABBVIE : to Present Data From Its Migraine Portfolio at the 2021 International Headache Co..
PR
09/08AbbVie to Present Data From Its Migraine Portfolio at the 2021 International Headache C..
CI
09/07ABBVIE : BTL Industries Settles Patent Infringement Claims Against AbbVie
MT
1  2  3  4  5  6  7  8  9  10Next
Upcoming event on ABBVIE INC.
10/29/21